Advertisement
UK markets close in 8 hours 13 minutes

  • FTSE 100

    8,290.99
    +77.50 (+0.94%)
     

  • FTSE 250

    20,300.46
    +135.92 (+0.67%)
     

  • AIM

    771.75
    +0.22 (+0.03%)
     

  • GBP/EUR

    1.1648
    -0.0012 (-0.10%)
     

  • GBP/USD

    1.2539
    -0.0025 (-0.20%)
     

  • Bitcoin GBP

    50,762.78
    -483.79 (-0.94%)
     

  • CMC Crypto 200

    1,367.60
    +2.47 (+0.18%)
     

  • S&P 500

    5,180.74
    +52.95 (+1.03%)
     

  • DOW

    38,852.27
    +176.59 (+0.46%)
     

  • CRUDE OIL

    78.47
    -0.01 (-0.01%)
     

  • GOLD FUTURES

    2,327.60
    -3.60 (-0.15%)
     

  • NIKKEI 225

    38,835.10
    +599.03 (+1.57%)
     

  • HANG SENG

    18,482.30
    -96.00 (-0.52%)
     

  • DAX

    18,246.84
    +71.63 (+0.39%)
     

  • CAC 40

    8,035.29
    +38.65 (+0.48%)
     
Money:

The retirement income gap no-one is talking about

People are living longer than ever before and this can impact how you plan for retirement

BUZZ-AstraZeneca: Pfizer may turn M&A sights on Mylan -Jefferies

Reuters - UK Focus

** Pfizer (NYSE: PFE - news) can resume its pursuit of AstraZeneca (NYSE: AZN - news) from today as 6-month cooling-off period ends but chances of a fresh bid seen as slim, especially after the U.S. drugmaker's big oncology deal with Merck KGaA (Other OTC: MKGAF - news) last week.

** Jefferies analysts reckon Mylan (NasdaqGS: MYL - news) , which is buying some of Abbott's established drugs, now the most likely target for Pfizer, with GlaxoSmithKline "a wild card", since buying top UK drugmaker would provoke political storm.

** Actavis (NYSE: ACT - news) , once seen as main "Plan B" target for Pfizer, may now also be off the table following its proposed acquisition of Allergan (NYSE: AGN - news) .

** AstraZeneca shares are flat in early trade. (RM (LSE: RM.L - news) : ben.hirschler.thomsonreuters.com@reuters.net)